\u30d7\u30ec\u30b7\u30b8\u30e7\u30f3\u30fb\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u306e\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3042\u308bGuardant Health, Inc.\u3068\u3001\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u306e\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30fb\u30a8\u30d3\u30c7\u30f3\u30b9\u30fb\u30c7\u30fc\u30bf\u304a\u3088\u3073AI SaaS\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3042\u308bConcertAI\u793e\u306f\u3001\u30d0\u30a4\u30aa\u88fd\u85ac\u4f01\u696d\u304c\u3001\u304c\u3093\u6cbb\u7642\u306e\u7d99\u7d9a\u306b\u308f\u305f\u3063\u3066\u3001\u5305\u62ec\u7684\u306a\u60a3\u8005\u306e\u96fb\u5b50\u30ab\u30eb\u30c6\uff08EMR\uff09\u30c7\u30fc\u30bf\u3068\u30b2\u30ce\u30e0\u304a\u3088\u3073\u30a8\u30d4\u30b2\u30ce\u30e0\u306e\u816b\u760d\u30d7\u30ed\u30d5\u30a1\u30a4\u30ea\u30f3\u30b0\u60c5\u5831\u306e\u4e21\u65b9\u3092\u7d71\u5408\u3057\u305f\u521d\u306e\u30de\u30eb\u30c1\u30e2\u30fc\u30c0\u30eb\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30c7\u30fc\u30bf\uff08RWD\uff09\u306b\u30a2\u30af\u30bb\u30b9\u3067\u304d\u308b\u3088\u3046\u306b\u3059\u308b\u5354\u696d\u5951\u7d04\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>
An individual patient’s cancer is complex, with response to medicines being determined by multiple factors, including specific driver mutations from the cancer, previous therapies and acquired resistance to those therapies. The creation of a joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma collaborators to better interpret disease biology and identify drivers and timing of tumor evolution as well as intrinsic and acquired resistance mechanisms. These are critical insights with causal associations that can guide the design of clinical trials and effective therapeutics. Through this collaboration, biopharmaceutical company partners can now leverage the joint dataset, combined analytics capability, AI SaaS solutions and precision oncology footprint of ConcertAI and Guardant Health.<\/p>
“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies. It represents another milestone in Guardant’s mission to conquer cancer with data.”<\/p>
\u3053\u306e\u7d71\u5408\u30c7\u30fc\u30bf\u63d0\u4f9b\u306f\u3001\u5404\u816b\u760d\u304c\u69cb\u6210\u3059\u308b\u56fa\u6709\u306e\u30e1\u30c1\u30eb\u5316\u30d1\u30bf\u30fc\u30f3\u3092\u7279\u5b9a\u3059\u308b\u306e\u306b\u5f79\u7acb\u3064\u5e83\u7bc4\u306a\u30e1\u30c1\u30ed\u30fc\u30e0\u30fb\u30d1\u30cd\u30eb\u3092\u542b\u3080Guardant Infinity\u30b9\u30de\u30fc\u30c8\u30fb\u30ea\u30ad\u30c3\u30c9\u30fb\u30d0\u30a4\u30aa\u30d7\u30b7\u30fc\u30fb\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u5b9f\u884c\u3055\u308c\u308b\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u691c\u67fb\u304b\u3089\u306e\u30e1\u30c1\u30eb\u5316\u30c7\u30fc\u30bf\u3092\u542b\u3080\u3068\u3044\u3046\u70b9\u3067\u3001\u696d\u754c\u3067\u3082\u30e6\u30cb\u30fc\u30af\u306a\u3082\u306e\u3068\u306a\u308a\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u3053\u308c\u307e\u3067\u306e\u81e8\u5e8a\u958b\u767a\u3067\u306f\u307b\u3068\u3093\u3069\u672a\u89e3\u660e\u3067\u3042\u3063\u305f\u91cd\u8981\u306a\u65b0\u6b21\u5143\u306e\u7814\u7a76\u6d1e\u5bdf\u3092\u63d0\u4f9b\u3057\u307e\u3059\u3002\u307e\u305f\u3001\u3053\u306e\u30c7\u30fc\u30bf\u30bb\u30c3\u30c8\u306f\u3001\u65e9\u671f\u304c\u3093\u306b\u304a\u3051\u308b\u6b8b\u5b58\u75c5\u5909\u3084\u518d\u767a\u306e\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u304b\u3089\u3001\u9032\u884c\u304c\u3093\u306b\u304a\u3051\u308b\u6cbb\u7642\u6cd5\u306e\u9078\u629e\u3084\u6cbb\u7642\u52b9\u679c\u306e\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u307e\u3067\u3001\u304c\u3093\u6cbb\u7642\u306e\u9023\u7d9a\u6027\u3092\u7db2\u7f85\u3059\u308b\u30b2\u30ce\u30e0\u30fb\u30d7\u30ed\u30d5\u30a1\u30a4\u30ea\u30f3\u30b0\u30fb\u30c7\u30fc\u30bf\u3092\u542b\u3080\u3068\u3044\u3046\u70b9\u3067\u3082\u30e6\u30cb\u30fc\u30af\u3067\u3059\u3002<\/p>
“By integrating ConcertAI’s extensive clinical dataset and enterprise AI with the new data on tumor methylation patterns enabled by Guardant Health’s innovative sequencing technology, we can partner with biopharma researchers to enable novel approaches to cancer therapy discovery, clinical study design, and innovative models for clinical development,” said Jeff Elton, Ph.D., MBA, CEO of ConcertAI. “Providing biopharma collaborators with access to integrated data of this depth and scale will help accelerate new medicines needed by patients with cancer, especially those with few available targeted therapy options.”<\/p>